17/06/2026
đī¸ āύāĻžāϰā§āϰ āĻ āĻĒā§āϰā§āώā§āϰ āϏā§āĻŦāĻžāϏā§āĻĨā§āϝ āϏāĻā§āϤāύāϤāĻž
āϞāĻŋāĻāĻžāϰ āĻā§āϝāĻžāύā§āϏāĻžāϰ (Liver Cancer) â Part 1
đŠē āĻāĻžāύā§āύ, āϏāĻā§āϤāύ āĻšā§āύ, āĻā§āĻŦāύ āĻŦāĻžāĻāĻāĻžāύ
āĻŦāϰā§āϤāĻŽāĻžāύ āϏāĻŽā§ā§ āϞāĻŋāĻāĻžāϰ āĻā§āϝāĻžāύā§āϏāĻžāϰ āĻŦāĻŋāĻļā§āĻŦāĻŦā§āϝāĻžāĻĒā§ āĻĻā§āϰā§āϤ āĻŦā§āĻĻā§āϧāĻŋ āĻĒāĻžāĻā§āĻž āĻā§āϝāĻžāύā§āϏāĻžāϰāĻā§āϞā§āϰ āĻŽāϧā§āϝ⧠āĻ
āύā§āϝāϤāĻŽāĨ¤ āĻĒā§āϰāϤāĻŋ āĻŦāĻāϰ āĻ
āϏāĻāĻā§āϝ āĻŽāĻžāύā§āώ āĻāĻ āϰā§āĻā§ āĻāĻā§āϰāĻžāύā§āϤ āĻšāĻā§āĻā§āύāĨ¤ āĻ
āύā§āĻā§āĻ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āĻĒāϰā§āϝāĻžā§ā§ āϰā§āĻāĻāĻŋ āĻļāύāĻžāĻā§āϤ āĻāϰāϤ⧠āύāĻž āĻĒāĻžāϰāĻžā§ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏā§āϝā§āĻ āĻšāĻžāϰāĻŋā§ā§ āĻĢā§āϞā§āύāĨ¤
āĻĻā§āĻāĻāĻāύāĻ āĻšāϞā§āĻ āϏāϤā§āϝ, āϞāĻŋāĻāĻžāϰ āĻā§āϝāĻžāύā§āϏāĻžāϰā§āϰ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āϞāĻā§āώāĻŖāĻā§āϞ⧠āĻ
āύā§āĻ āϏāĻŽā§ āĻā§āĻŦ āϏāĻžāϧāĻžāϰāĻŖ āĻŽāύ⧠āĻšā§āĨ¤ āĻĢāϞ⧠āϰā§āĻāĻāĻŋ āύā§āϰāĻŦā§ āĻ
āĻā§āϰāϏāϰ āĻšāϤ⧠āĻĨāĻžāĻā§ āĻāĻŦāĻ āϧāϰāĻž āĻĒā§āĻžāϰ āϏāĻŽā§ āĻ
āύā§āĻ āĻā§āώā§āϤā§āϰ⧠āĻāĻāĻŋāϞ āĻ
āĻŦāϏā§āĻĨāĻžā§ āĻĒā§āĻāĻā§ āϝāĻžā§āĨ¤
āϤāĻŦā§ āĻāĻļāĻžāϰ āĻāĻĨāĻž āĻšāϞā§âāϏāĻŽā§ā§ āĻļāύāĻžāĻā§āϤ āĻāϰāĻž āĻā§āϞ⧠āϞāĻŋāĻāĻžāϰ āĻā§āϝāĻžāύā§āϏāĻžāϰā§āϰ āϏāĻĢāϞ āĻāĻŋāĻāĻŋā§āϏāĻž āϏāĻŽā§āĻāĻŦāĨ¤
---
đ āϞāĻŋāĻāĻžāϰ āĻā§āϝāĻžāύā§āϏāĻžāϰ āĻā§?
āϞāĻŋāĻāĻžāϰ āĻā§āϝāĻžāύā§āϏāĻžāϰ (Liver Cancer) āĻšāϞ⧠āϝāĻā§āϤā§āϰ āĻā§āώ āĻĨā§āĻā§ āĻā§āĻĒāύā§āύ āĻāĻāĻāĻŋ āĻŽā§āϝāĻžāϞāĻŋāĻāύā§āϝāĻžāύā§āĻ (āĻā§āϝāĻžāύā§āϏāĻžāϰāĻāύāĻŋāϤ) āϰā§āĻāĨ¤
āĻāĻāĻŋ āĻĻā§āĻ āϧāϰāύā§āϰ āĻšāϤ⧠āĻĒāĻžāϰā§:
ā§§ī¸âŖ Primary Liver Cancer
āϝāĻāύ āĻā§āϝāĻžāύā§āϏāĻžāϰ āϏāϰāĻžāϏāϰāĻŋ āϞāĻŋāĻāĻžāϰ āĻĨā§āĻā§āĻ āĻļā§āϰ⧠āĻšā§āĨ¤
āϏāĻŦāĻā§ā§ā§ āϏāĻžāϧāĻžāϰāĻŖ āϧāϰāύ:
âī¸ Hepatocellular Carcinoma (HCC)
āĻ
āύā§āϝāĻžāύā§āϝ āϧāϰāύ:
âī¸ Cholangiocarcinoma
âī¸ Hepatoblastoma (āĻļāĻŋāĻļā§āĻĻā§āϰ āĻŽāϧā§āϝā§)
⧍ī¸âŖ Secondary (Metastatic) Liver Cancer
āϝāĻāύ āĻļāϰā§āϰā§āϰ āĻ
āύā§āϝ āĻā§āύ⧠āĻ
āĻā§āĻā§ (āϝā§āĻŽāύ āĻā§āϞāύ, āĻĢā§āϏāĻĢā§āϏ, āϏā§āϤāύ āĻāϤā§āϝāĻžāĻĻāĻŋ) āĻā§āĻĒāύā§āύ āĻā§āϝāĻžāύā§āϏāĻžāϰ āϞāĻŋāĻāĻžāϰ⧠āĻā§āĻŋā§ā§ āĻĒā§ā§āĨ¤
---
â ī¸ āĻāĻžāϰāĻž āĻŦā§āĻļāĻŋ āĻā§āĻāĻāĻŋāϤā§?
āύāĻŋāĻā§āϰ āĻāĻžāϰāĻŖāĻā§āϞ⧠āϞāĻŋāĻāĻžāϰ āĻā§āϝāĻžāύā§āϏāĻžāϰā§āϰ āĻā§āĻāĻāĻŋ āĻāϞā§āϞā§āĻāϝā§āĻā§āϝāĻāĻžāĻŦā§ āĻŦāĻžā§āĻžāϤ⧠āĻĒāĻžāϰā§â
âī¸ Hepatitis B Virus (HBV)
âī¸ Hepatitis C Virus (HCV)
âī¸ Liver Cirrhosis
âī¸ āĻĻā§āϰā§āĻāĻĻāĻŋāύ āĻ
āϤāĻŋāϰāĻŋāĻā§āϤ āĻ
ā§āϝāĻžāϞāĻā§āĻšāϞ āϏā§āĻŦāύ
âī¸ Fatty Liver Disease (NAFLD/NASH)
âī¸ Diabetes āĻ Obesity
âī¸ Aflatoxin-āϝā§āĻā§āϤ āĻĻā§āώāĻŋāϤ āĻāĻžāĻĻā§āϝ
âī¸ āĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ āĻāϤāĻŋāĻšāĻžāϏ
---
đ¨ āϞāĻā§āώāĻŖ āĻ āĻāĻĒāϏāϰā§āĻ
āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āϞāĻā§āώāĻŖ
đ¸ āĻā§āώā§āϧāĻžāĻŽāύā§āĻĻāĻž
đ¸ āĻĻā§āϰā§āϤ āĻāĻāύ āĻāĻŽā§ āϝāĻžāĻā§āĻž
đ¸ āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻ āĻā§āϞāĻžāύā§āϤāĻŋ
đ¸ āĻšāĻžāϞāĻāĻž āĻĒā§āĻāĻŦā§āϝāĻĨāĻž
đ¸ āĻāĻžāĻŦāĻžāϰā§āϰ āĻĒāϰ āĻ
āϏā§āĻŦāϏā§āϤāĻŋ
āĻ
āĻā§āϰāϏāϰ āĻĒāϰā§āϝāĻžā§ā§āϰ āϞāĻā§āώāĻŖ
đ´ āĻĒā§āĻā§āϰ āĻĄāĻžāύ āĻĒāĻžāĻļā§ āĻŦā§āϝāĻĨāĻž
đ´ āĻĒā§āĻ āĻĢā§āϞāĻž (Ascites)
đ´ āĻāύā§āĻĄāĻŋāϏ
đ´ āĻŦāĻŽāĻŋ āĻŦāĻŽāĻŋ āĻāĻžāĻŦ
đ´ āϞāĻŋāĻāĻžāϰ āĻŦā§ āĻšā§ā§ āϝāĻžāĻā§āĻž
đ´ āĻļāϰā§āϰ āĻā§āϞāĻāĻžāύā§
đ´ āϰāĻā§āϤāĻā§āώāϰāĻŖ āĻĒā§āϰāĻŦāĻŖāϤāĻž
---
đ§Ē āĻāĻŋāĻāĻžāĻŦā§ āϰā§āĻ āύāĻŋāϰā§āĻŖā§ āĻāϰāĻž āĻšā§?
đ Clinical Assessment
āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻ āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž
𩸠Blood Tests
âī¸ AFP (Alpha Fetoprotein)
âī¸ Liver Function Test (LFT)
âī¸ Viral Marker (HBV/HCV)
đĨī¸ Imaging
âī¸ Ultrasound
âī¸ Triphasic CT Scan
âī¸ MRI Liver
âī¸ PET-CT (āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ āĻā§āώā§āϤā§āϰā§)
đŦ Biopsy
āĻĒā§āϰā§ā§āĻāύ⧠āĻāĻŋāϏā§āϝ⧠āĻĒāϰā§āĻā§āώāĻž āĻāϰ⧠āύāĻŋāĻļā§āĻāĻŋāϤ āϰā§āĻ āύāĻŋāϰā§āĻŖā§ āĻāϰāĻž āĻšā§āĨ¤
---
đ Liver Cancer Staging
đĸ Stage I
āĻā§āϝāĻžāύā§āϏāĻžāϰ āĻļā§āϧā§āĻŽāĻžāϤā§āϰ āϞāĻŋāĻāĻžāϰā§āϰ āĻŽāϧā§āϝ⧠āϏā§āĻŽāĻžāĻŦāĻĻā§āϧ
đĄ Stage II
āĻāĻāĻžāϧāĻŋāĻ āĻāĻŋāĻāĻŽāĻžāϰ āĻŦāĻž āϰāĻā§āϤāύāĻžāϞ⧠āĻāĻā§āϰāĻžāύā§āϤ
đ Stage III
āύāĻŋāĻāĻāĻŦāϰā§āϤ⧠āĻ
āĻā§āĻā§ āĻā§āĻžāϤ⧠āĻļā§āϰ⧠āĻāϰā§āĻā§
đ´ Stage IV
āĻĻā§āϰā§āϰ āĻ
āĻā§āĻā§ (āĻĢā§āϏāĻĢā§āϏ, āĻšāĻžā§ āĻāϤā§āϝāĻžāĻĻāĻŋ) āĻā§āĻŋā§ā§ āĻĒā§ā§āĻā§
---
đ āĻāϧā§āύāĻŋāĻ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒāĻĻā§āϧāϤāĻŋ
đš Surgery
âī¸ Liver Resection
âī¸ Liver Transplantation
đš Local Therapies
âī¸ Radiofrequency Ablation (RFA)
âī¸ Microwave Ablation (MWA)
âī¸ TACE
âī¸ TARE / Y-90 Radioembolization
đš Targeted Therapy
âī¸ Sorafenib
âī¸ Lenvatinib
âī¸ Regorafenib
âī¸ Cabozantinib
đš Immunotherapy
âī¸ Atezolizumab + Bevacizumab
âī¸ Durvalumab
âī¸ Nivolumab
âī¸ Pembrolizumab
---
đĄī¸ āĻĒā§āϰāϤāĻŋāϰā§āϧā§āϰ āĻāĻĒāĻžā§
âī¸ Hepatitis B Vaccine āĻā§āϰāĻšāĻŖ āĻāϰā§āύ
âī¸ āĻ
ā§āϝāĻžāϞāĻā§āĻšāϞ āĻĒāϰāĻŋāĻšāĻžāϰ āĻāϰā§āύ
âī¸ āĻāĻāύ āύāĻŋā§āύā§āϤā§āϰāĻŖā§ āϰāĻžāĻā§āύ
âī¸ Fatty Liver-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻž āĻāϰā§āύ
âī¸ āύāĻŋā§āĻŽāĻŋāϤ āϏā§āĻŦāĻžāϏā§āĻĨā§āϝ āĻĒāϰā§āĻā§āώāĻž āĻāϰā§āύ
âī¸ Hepatitis B āĻ C āĻĻā§āϰā§āϤ āĻļāύāĻžāĻā§āϤ āĻ āĻāĻŋāĻāĻŋā§āϏāĻž āĻāϰā§āύ
---
â¤ī¸ āĻŽāύ⧠āϰāĻžāĻāĻŦā§āύ
đ āϞāĻŋāĻāĻžāϰ āĻā§āϝāĻžāύā§āϏāĻžāϰ āϝāϤ āĻāĻā§ āϧāϰāĻž āĻĒā§āĻŦā§, āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏāĻĢāϞāϤāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϤāϤ āĻŦā§āĻļāĻŋāĨ¤
đ āĻĻā§āϰā§āĻāĻĻāĻŋāύā§āϰ āĻĢā§āϝāĻžāĻāĻŋ āϞāĻŋāĻāĻžāϰ, āϏāĻŋāϰā§āϏāĻŋāϏ āĻŦāĻž āĻšā§āĻĒāĻžāĻāĻžāĻāĻāĻŋāϏ āĻĨāĻžāĻāϞ⧠āύāĻŋā§āĻŽāĻŋāϤ āϏā§āĻā§āϰāĻŋāύāĻŋāĻ āĻ
āϤā§āϝāύā§āϤ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
đ āĻāύā§āĻĄāĻŋāϏ, āĻ
āĻāĻžāϰāĻŖā§ āĻāĻāύ āĻāĻŽā§ āϝāĻžāĻā§āĻž āĻŦāĻž āĻĻā§āϰā§āĻāĻĻāĻŋāύ āĻĒā§āĻā§āϰ āϏāĻŽāϏā§āϝāĻžāĻā§ āĻāĻāύā§āĻ āĻ
āĻŦāĻšā§āϞāĻž āĻāϰāĻŦā§āύ āύāĻžāĨ¤
---
đĸ Part-2 āϤ⧠āĻāϞā§āĻāύāĻž āĻāϰāĻŦ:
âī¸ Functional Medicine & Liver Cancer
âī¸ Integrative Oncology Approach
âī¸ Nutrition & Lifestyle Strategies
âī¸ Supportive Care During Cancer Treatment
---
đ āϤāĻĨā§āϝāϏā§āϤā§āϰ:
âĸ World Health Organization (WHO)
âĸ American Cancer Society (ACS)
âĸ NCCN Guidelines
âĸ ESMO Guidelines
âĸ Harrison's Principles of Internal Medicine
âĸ DeVita, Hellman & Rosenberg's Cancer Principles & Practice of Oncology
---
â¤ī¸ āϏāĻā§āϤāύ āĻšā§āύ, āĻ
āύā§āϝāĻā§āĻ āϏāĻā§āϤāύ āĻāϰā§āύāĨ¤
đ Early Detection Saves Lives.
đŦ āĻāĻĒāύāĻžāϰ āĻā§āύ⧠āĻĒā§āϰāĻļā§āύ āĻĨāĻžāĻāϞ⧠āĻāĻŽā§āύā§āĻā§ āĻāĻžāύāĻžāύāĨ¤
đ āĻĒā§āϏā§āĻāĻāĻŋ āĻāĻžāϞ⧠āϞāĻžāĻāϞ⧠Like, Comment, Share āĻāϰā§āύ āĻāĻŦāĻ Follow āĻāϰ⧠āĻāĻŽāĻžāĻĻā§āϰ āϏāĻžāĻĨā§āĻ āĻĨāĻžāĻā§āύāĨ¤